香港六合彩中特网

Professor Lignani undertook his PhD degree in Experimental Neuroscience at the University of Genova in collaboration with Italian Institute of Technology, following a听BSc in Medical Biotechnologies at the University of Milan and听MSc in Medical-pharmaceutical Biotechnologies (Neuroscience) at the University of Genova.

He joined 香港六合彩中特网 Queen Square Institute of Neurology (IoN) as a Research Associate in 2014, and was a Research Fellow at IoN from 2014-18. He became Senior and then Principal Research Fellow at ION, before becoming an听Associate Professor in 2022, when he also founded the听EpilesyGTx company. He is the theme lead for advance therapies and disease modifications at the听Epilepsy Research Institute UK which was founded in 2023.

Professor Lignani has received numerous awards and fellowships including听Horizon 2020- Marie Curie Individual fellowship (2016-18);听Epilepsy Research UK Emerging Leader fellowship (2018-21);听Young Investigator Harinarayan Award by International League against Epilepsy (ILAE) in 2021;听Honorary Ambassador of Genova (Italy) in the World by听the Mayor of Genova in 2022;听Michael Prize for the best scientific contribution to progress in the field of Epilepsy in 2023; and ILAE European Young Investigator in 2024. He became听Athena Swan Lead at the ION in 2022.

Professor Lignani's lab focusses on听finding novel gene therapy approaches for intractable neurological diseases, with rapid potential for translation, using听cutting-edge molecular technologies such as CRISPR and novel promoters to overcome current limitations to gene therapy and develop new approaches for currently untreatable neurodevelopmental genetic diseases such as Dravet Syndrome, Focal Cortical Dysplasia, Episodic Ataxia Type 1 and Autism Spectrum Disorders.听

The lab also researches听novel therapies for adult neurological diseases such as acquired pharmaco-resistant epilepsies and Alzheimer鈥檚 disease, and听developed the first gene therapy approach based on CRISPR to cure genetic epilepsies caused by haploinsufficiency and acquired pharmaco-resistance epilepsies. He also founded epilepsy gene therapy spinout company (EpilepsyGTx), with other 香港六合彩中特网 colleagues (Profs Dimitri Kullmann, Matthew Walker and Stephanie Schorge) and听support from听香港六合彩中特网 Business听(香港六合彩中特网B) and the听香港六合彩中特网 Tech Fund.听

鈥淒elivering my inaugural lecture was a truly wonderful experience. As I prepared for the lecture, I recalled about many precious memories from my childhood and scientific career. Most importantly, I was reminded of the many people who helped me achieve this dream. I am deeply grateful to my family for their unwavering support. I extend my deepest thanks to my former supervisors鈥擯rofessors Benfenati, Baldelli, Schorge, and Kullmann鈥攚hose guidance made this achievement possible. I also want to thank all my lab members, whose belief in me and hard work were crucial in reaching this milestone. Additionally, I would like to thank my collaborators and colleagues with whom I shared ideas. Special thanks go to Professor Plun-Favreau and Professor Kullmann for the opening, closing, and vote of thanks. Finally, I am profoundly thankful to the Institute of Neurology for giving me this opportunity.鈥澨齈rofessor Gabriele Lignani听